ev-201, ev-301 and unite: enfortumab vedotin in advanced urothelial cancer
Published 3 years ago • 309 plays • Length 6:01Download video MP4
Download video MP3
Similar videos
-
4:16
unite: enfortumab vedotin in advanced urothelial cancer
-
2:58
ev-201: enfortumab vedotin for cisplatin-ineligible bladder cancer
-
2:20
ev-201: enfortumab vedotin for bladder cancer
-
4:38
ev-301: enfortumab vedotin boosts advanced urothelial cancer survival | thomas powles
-
3:07
enfortumab vedotin in urothelial cancer
-
3:24
enfortumab vedotin as treatment for urothelial carcinomas
-
0:49
evolving landscape of urothelial cancer treatment: erdafitinib or enfortumab vedotin?
-
4:15
ev-201: enfortumab an option for cisplatin-ineligible advanced uc | arjun balar
-
4:22
checkmate 274 & ev-301: highlights in uc from asco gu
-
1:58
enfortumab vedotin for the treatment of advanced urothelial cancer
-
1:08
the future of enfortumab vedotin in different stages bladder cancer
-
3:07
ev-301 update reinforces third-line enfortumab vedotin benefit in advanced uc | jonathan rosenberg
-
8:27
urothelial carcinoma: ev-301 update from asco 2022
-
0:35
ev-302: 1l enfortumab vedotin in combination with pembrolizumab
-
0:50
enfortumab vedotin appears well-tolerated and active in advanced bladder cancers
-
2:52
enfortumab vedotin in urothelial cancer
-
2:09
ev-103: neoadjuvant enfortumab vedotin in cis-ineligible mibc
-
2:10
initial ev-103 results: enfortumab vedotin plus pembrolizumab for urothelial carcinoma
-
12:58
treatment of advanced urothelial carcinoma – a discussion of ev-301